Transgene Reports First Patient Dosed in Phase 1 BT-001 Trial for Rectal Cancer

• Transgene announced today that the first patient received treatment in the Phase 1 OV-PRIME-R trial for localized rectal cancer.
• The University of Copenhagen-sponsored study tests BT-001, co-developed with BioInvent, followed by pembrolizumab in patients with proficient mismatch repair status.
• The trial evaluates safety, tolerability and efficacy before standard surgery, aiming to reduce relapse risk and potentially avoid surgery.
• Previously reported clinical findings showed BT-001 was well tolerated and stimulated antitumor immune responses in patients with treatment-resistant metastatic cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050200OMX_____CNEWS_EN_GNW1001301885_en) on November 05, 2026, and is solely responsible for the information contained therein.